Zaida Casado-Garcia

Valencia, VC, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 76 publications

A high-penetrance intergenic variant at 9p21 confers melanoma susceptibility.

A high-penetrance intergenic variant at 9p21 confers melanoma susceptibility.

Journal: Research square
Published: May 25, 2026

A high-penetrance intergenic variant at 9p21 confers melanoma susceptibility.

A high-penetrance intergenic variant at 9p21 confers melanoma susceptibility.

Journal: Research square
Published: May 25, 2026

Melanocortin-1 receptor variants and telomerase reverse transcriptase promoter mutations as prognostic biomarkers in stage IIB-IIC melanoma.

Melanocortin-1 receptor variants and telomerase reverse transcriptase promoter mutations as prognostic biomarkers in stage IIB-IIC melanoma.

Journal: Melanoma research
Published: May 11, 2026

KIT Mutations Are More Common in Mucosal than Acral Melanoma: A Case-Series of 152 Patients from a Single Centre.

KIT Mutations Are More Common in Mucosal than Acral Melanoma: A Case-Series of 152 Patients from a Single Centre.

Journal: Biomedicines
Published: April 21, 2026

Association Between pTERT Promoter Mutation Subtypes and Survival Outcomes in BRAF-Mutant Metastatic Melanoma Treated With BRAF/MEK Inhibitors: An Exploratory Study.

Association Between pTERT Promoter Mutation Subtypes and Survival Outcomes in BRAF-Mutant Metastatic Melanoma Treated With BRAF/MEK Inhibitors: An Exploratory Study.

Journal: International journal of dermatology
Published: March 17, 2026

Comparison of Nonacral Cutaneous Lentiginous Melanomas According to the Degree of Solar Elastosis: Support for the New World Health Organization Classification.

Comparison of Nonacral Cutaneous Lentiginous Melanomas According to the Degree of Solar Elastosis: Support for the New World Health Organization Classification.

Journal: Actas dermo-sifiliograficas
Published: November 24, 2024

Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01).

Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: October 08, 2024

Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study.

Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study.

Journal: Cancers
Published: September 29, 2023

Editorial: Molecular genetics of cutaneous melanoma: current status and future direction-volume II.

Editorial: Molecular genetics of cutaneous melanoma: current status and future direction-volume II.

Journal: Frontiers in molecular biosciences
Published: August 07, 2023

Molecular Profile of Subungual Melanoma: A MelaNostrum Consortium Study of 68 Cases Reporting BRAF, NRAS, KIT, and TERT Promoter Status.

Molecular Profile of Subungual Melanoma: A MelaNostrum Consortium Study of 68 Cases Reporting BRAF, NRAS, KIT, and TERT Promoter Status.

Journal: Dermatology (Basel, Switzerland)
Published: July 22, 2023

High- and intermediate-risk susceptibility variants in melanoma families from the Mediterranean area: A multicentre cohort from the MelaNostrum Consortium.

High- and intermediate-risk susceptibility variants in melanoma families from the Mediterranean area: A multicentre cohort from the MelaNostrum Consortium.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: June 01, 2023

The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer-A GEICO Study.

The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer-A GEICO Study.

Journal: Cancers
Published: April 20, 2023
Showing 1-12 of 76

Last Updated: 09/26/2026